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Traditionally considered as a critical intermediate in the toxic and carcinogenic response
to dioxin (2,3,7,8-tetrachlorodibenzo-p-dioxin, TCDD), the Aryl hydrocarbon/Dioxin
receptor (AhR) has proven to be also an important regulator of cell physiology and
organ homeostasis. AhR has become an interesting and actual area of research mainly
boosted by a significant number of recent studies analyzing its contribution to the
proper functioning of the immune, hepatic, cardiovascular, vascular and reproductive
systems. At the cellular level, AhR establishes functional interactions with signaling
pathways governing cell proliferation and cell cycle, cell morphology, cell adhesion and
cell migration. Two exciting new aspects in AhR biology deal with its implication in the
control of cell differentiation and its more than likely involvement in cell pluripotency
and stemness. In fact, it is possible that AhR could help modulate the balance
between differentiation and pluripotency in normal and transformed tumor cells. At the
molecular level, AhR regulates an increasingly large array of physiologically relevant genes
either by traditional transcription-dependent mechanisms or by unforeseen processes
involving genomic insulators, chromatin dynamics and the transcription of mobile genetic
elements. AhR is also closely related to epigenetics, not only from the point of view
of target gene expression but also with respect to its own regulation by promoter
methylation. It is reasonable to consider that deregulation of these many functions could
have a causative role, or at least contribute to, human disease. Consequently, several
laboratories have proposed that AhR could be a valuable tool as diagnostic marker and/or
therapeutic target in human pathologies. An additional point of interest is the possibility
of regulating AhR activity by endogenous non-toxic low weight molecules agonist or
antagonist molecules that could be present or included in the diet. In this review, we will
address these molecular and functional features of AhR biology within physiological and
pathological contexts.
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INTRODUCTION
Since the early 90’s, the Aryl hydrocarbon/Dioxin receptor (AhR) has been defined as an
environmental-sensor PAS (Period [Per]-Aryl hydrocarbon receptor nuclear translocator [Arnt]-
Single minded [Sim]) protein structurally included within the class I of basic helix-loop-helix
transcriptional regulators (Burbach et al., 1992; Ema et al., 1992; Swanson and Bradfield, 1993;
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Hankinson, 1995) with major roles in xenobiotic-induced
toxicity and carcinogenicity (Boffetta et al., 2011; Pohjanvirta,
2012). A distinctive feature of AhR is that, up to date,
is among the only member of PAS proteins known to be
activated by ligands (Bersten et al., 2013). Among the ample
diversity of environmental xenobiotics, polycyclic aromatic
hydrocarbons have been extensively studied as AhR ligands, with
a particularly intense investigation on the human carcinogen
2,3,7,8-tetrachlorodibenzo-p-dioxin (Dioxin, TCDD; Kerkvliet
et al., 2002). The molecular pathway leading to AhR activation
by exogenous ligands (e.g., TCDD) has been extensively studied.
Unliganded AhR resides in the cytosolic compartment of the cell
bound to a molecular chaperone complex that at least contains
two molecules of Hsp90, XAP2 and p23. Upon ligand binding,
the receptor translocates to the nucleus and heterodimerizes
with the class II bHLH protein ARNT/HIF1β (Aryl hydrocarbon
receptor nuclear translocator/Hypoxia-inducible factor 1β)
(Swanson and Bradfield, 1993; Swanson et al., 1995; Crews,
1998; Whitlock, 1999; Nebert and Dalton, 2006). Many
reports have described at the molecular level the mechanism
of AhR-dependent transcription (Pohjanvirta, 2012). Despite
some controversy about the existence of an endogenous
ligand(-s) that binds AhR in the absence of xenobiotics, once
activated, AhR translocates to the cell nucleus to interact with
ARNT in order to form a functional AhR-ARNT heterodimer
(Reyes et al., 1992). This heterodimer binds to a set of co-
activators and/or co-repressors and the resulting complex will
recognize a consensus XRE binding site (xenobiotic responsive
element; 5′-GCGTG-3′) located in the upstream r(Mimura
et al., 1999)egulatory region of target genes (e.g., cytochromes
P450 such as CYP1A1) (Hankinson, 1995, 2005; Whitlock,
1999). Following transcriptional regulation, the AhR-ARNT
heterodimer is disassembled from DNA and AhR is transported
to the cytosol for proteosomal degradation (Davarinos and
Pollenz, 1999; Ma and Baldwin, 2000; Santiago-Josefat et al.,
2001). Moreover, the AhR repressor (AhRR) has been identified
as a target gene of AhR, providing a novel mechanism of feedback
inhibition of AhR function in that a transcription factor directly
induces the expression of its repressor through binding to its
cognate regulatory sequence located in the promoter of the
target gene. This regulatory circuit involves the activation of AhR
by xenobiotics in order to induce AhRR expression, which, in
turn, will compete with AhR for ARNT heterodimerization. As
AhRR-ARNT heterodimers are transcriptionally inactive, AhR-
dependent gene expression results abolished by reduced AhR-
ARNT recruitment to the XRE sites located in the promoter of
responsive genes (Mimura et al., 1999).
Based on its functions as a mediator of the cellular response
to xenobiotics, initial human epidemiological studies alerted to
health authorities about the pathological effects likely attributable
to AhR-mediated activity including alterations in the immune
system, lipid metabolism, epithelial integrity, porphyria, liver
damage, thymic involution and cancer (Fingerhut et al., 1991;
Flesch-Janys et al., 1995). However, the generation of transgenic
mouse models led to a remarkable number of findings supporting
that AhR plays important physiological and homeostatic roles in
major organs and tissues. Among others, AhR-null mice (AhR-/-)
showed developmental defects in the hepatic, hematopoietic,
cardiovascular and immune systems (Fernandez-Salguero et al.,
1995, 1997; Schmidt et al., 1996; Mimura et al., 1997; Lahvis
et al., 2000, 2005). Recent evidences suggest the existence of
endogenous ligands for AhR (Nguyen and Bradfield, 2008)
triggering differential responses that could lead to cell-type
specific AhR-dependent effects. Additionally, AhR levels are
regulated by the proteasome (Davarinos and Pollenz, 1999; Ma
and Baldwin, 2000), and proteasome inhibition, in absence of
exogenous ligands, can activate AhR transcription (Santiago-
Josefat et al., 2001; Santiago-Josefat and Fernandez-Salguero,
2003). The physiological relevance of AhR is further supported
by its evolutionary conservation across metazoan phyla (Qin and
Powell-Coffman, 2004; Qin et al., 2006; Williams et al., 2014).
It is remarkable that invertebrate isoforms of AhR such as D.
melanogaster Spineless (Ss) does not have detoxifying functions
but it is instead required for eye, leg and wing development
(Céspedes et al., 2010). In C. elegans, AHR-1 appears essential
for neuronal differentiation and migration (Qin and Powell-
Coffman, 2004; Qin et al., 2006). The current view in the field
is that xenobiotic-dependent AhR functions in fact represent an
adaptive mechanism overlapping its physiologically conserved
roles.
In this review, we will discuss novel functions and regulatory
mechanisms of AhR that have improved our knowledge on
this receptor in the physiological and pathological contexts.
The first stages in AhR research involved great efforts to
discover and to characterize its many roles in mediating the
toxicity of dioxins and related compounds, with some initial
studies identifying homeostatic and developmental processes
requiring its activity. Recent investigations are discovering
new and exciting insights into AhR biology dealing with cell
differentiation and pluripotency, chromatin dynamics, activation
of mobile genetic elements, proliferation, epidermal barrier
function and immune regulation (Safe et al., 2013). An additional
aspect that is been recently considered is the potential beneficial
effect of including natural AhR ligands in the diet, with the aim
to maintain the endogenous AhR expression and activation that
supports normal cell functioning. Current and future work will
determine whether AhR intervention represents a useful tool to
treat certain human diseases.
NEW MECHANISMS OF AHR REGULATION
In the first part of this section, we will discuss recently identified
mechanisms through which AhR modulates gene expression
and that differ from classical transcriptional regulation. We
will focus on the activation of mobile genetic elements as
unexpected intermediates in the AhR-dependent control of
gene expression. In a second part, we will analyze the
impact of epigenetics in regulating AhR expression and in
how AhR could influence the epigenetic status of target
genes (Figure 1).
AhR in the Control of Gene Expression
through Mobile Genetic Elements
Transposable elements are no longer considered useless DNA
without a function in the genome. Accumulating evidence
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FIGURE 1 | Scheme summarizing new mechanisms of AhR regulation. Upon novel (non-toxic) ligand binding, AhR translocates to the nucleus and
heterodimerizes with its partner protein ARNT. (A) Transposable elements (TEs) located in upstream promoter and enhancer sequences contain transcription factor
binding sites (TFBSs) for gene regulation. AhR recognizes consensus XRE binding elements (xenobiotic responsive element; 5′-GCGTG-3′) in LINE-1, B1-X35S, and
Alu TEs. AhR-mediated regulation triggers the expression and mobilization of these TEs. (B) Epigenetics mechanisms regulating AhR expression and the status of its
target genes and microRNAs.
supports an important role for these mobile molecules in
development and disease (Beck et al., 2011; Hancks and
Kazazian, 2012; Solyom and Kazazian, 2012). Among them,
retrotransposons of the murine SINE (short interspersed nuclear
elements) and human Alu subfamilies account for close to 13%
of their respective genomes and, more importantly, they are
highly abundant in intronic and upstream promoter regions of
target genes (Lander et al., 2001; Versteeg et al., 2003; Kriegs
et al., 2007; de Koning et al., 2011). An intriguing feature of
transposable elements is their ability to carry binding sites for
well-known transcription factors, including OCT4 (POU5F1),
CTCF, SOX2, NANOG, p53 and ESR1 (Wang et al., 2007;
Bourque et al., 2008; Kunarso et al., 2010). Studies in mouse and
human embryonic stem cells estimate that transposable elements
provide nearly 25% of the binding sites for OCT4 and NANOG
transcription factors, suggesting that transposons have an active
influence in determining gene expression patterns (Wissing et al.,
2012; Friedli et al., 2014; Elbarbary et al., 2016). An intense
effort is currently underway to identify mobile genetic elements
whose activation could regulate cell functions under normal and
pathological conditions (Bennett et al., 2008; Fort et al., 2014;
Hung et al., 2015), as observed for the retrotransposon-mediated
oncogenic activation in human hepatocellular carcinoma (Shukla
et al., 2013).
Notably, the dioxin receptor is functionally connected to the
regulation of transposable elements. Early work has revealed
that AhR activation by the xenobiotic compound benzo-a-pyrene
(BaP) induced the expression of LINE-1 (long interspersed
nuclear element-1) retrotransposons in human cell lines from
cervical carcinoma (HeLa) and microvascular endothelium
(HMEC), and in mouse cells from smooth muscle (mVSMC) and
embryonic kidney (mK4). Interestingly, when the prototypical
AhR ligand TCDD (2,3,7,8-tetrachlorodibenzo-p-dioxin) was
used, LINE-1 induction was only observed in HeLa cells,
suggesting that LINE-1 retrotransposons may be modulated
by cell type-specific mechanisms of AhR activation (Teneng
et al., 2007). A latter study analyzing the LINE-1RP human
retrotransposon revealed that its effects on cell proliferation
and differentiation could be recapitulated by the activation
of endogenous LINE-1 elements by the AhR ligand BaP
(Ramos et al., 2011). Human exposure to low concentrations of
environmental carcinogens seems to contribute to tumorigenesis
(Lauber et al., 2004). In this regard, carcinogens present
in broiled meet seem to regulate LINE-1 retrotransposition
by an AhR-dependent process. Nanomolar concentrations of
food-borne 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine
(PhIP) and 2-amino-3,8-dimethyl-imidazo [4,5-f]quinoxaline
(MeIQx) were shown to induce LINE-1 mobilization by
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a mechanism that requires AhR, MAPK (mitogen-activated
protein kinase) and C/EBPβ (CCAAT enhancer binding protein-
β), suggesting a link between carcinogens, LINE-1 elements
and AhR (Okudaira et al., 2013). Surprisingly, however, the
tryptophan photoproduct and non-carcinogenic endogenous
AhR ligand FICZ (6 formylindolo[3,2-b]carbazole) induced
LINE-1 retrotransposition in human hepatocellular carcinoma
HuH-7 cells by a mechanism requiring ARNT and MAPK
but not AhR (Okudaira et al., 2010). One possible explanation
for these results is that bHLH/PAS proteins other than AhR
modulate the epigenetic status of active LINE-1 elements, so
that genome reorganization by FICZ-induced ARNT-mediated
LINE-1 transposition gives the cell an advantage for survival
(Okudaira et al., 2010). Although it appears very likely that AhR
modulates LINE-1 activation, future studies are needed to clarify
the molecular mechanisms and the signaling pathways involved.
AhR can regulate gene expression through non-autonomous
B1-SINE and Alu retroelements. We initially identified a novel
B1-SINE retrotransposon (named B1-X35S), widely represented
in the mouse genome, and that was particularly enriched in
upstream promoter regions (Roman et al., 2008). B1-X35S
was a conserved sequence harboring binding sites for AhR
(XRE) and for the E-box binding proteins Snail and Slug/Snai2.
Importantly, the AhR/ARNT heterodimer and Slug/Snai2 were
co-recruited under basal and ligand-induced conditions to B1-
X35S elements located in the promoter of developmental and
differentiation-related genes Lpp (cell-adhesion related lipoma
preferred partner), Tbc1d1 (Obesity risk gene), and Dad1
(Defender against cell death 1) (Roman et al., 2008). From a
functional point of view, ligandmediated AhR activation induced
the repression of these target genes in mouse hepatocellular
carcinoma Hepa-1 cells whereas mutation of AhR and Slug
binding sites restored basal gene expression (Román et al.,
2011a). Later studies investigating the molecular mechanisms
involved in the repressive activity of B1-X35S revealed that this
element has a potent autonomous insulator activity in vitro in
Hepa-1 cells and in vivo in zebrafish (Román et al., 2011b). A
central observation from this study was that AhR-dependent
repression of Lpp, Tbc1d1 and Dad1 (also Cabin 1 and Rtl1)
required the transcription of B1-X35S by a switch mechanism
involving RNA polymerase III and RNA polymerase II. That is,
the repression of target genes does not take place by a direct effect
of AhR on the transcription of their mRNAs (by RNA polymerase
II) but rather by a mechanism triggered by the non-coding
RNA transcripts produced from the B1-X35S retrotransposon
(Román et al., 2011a). The location of B1-X35S in between
the upstream enhancer and the promoter of target genes (e.g.,
Lpp, Tbc1d1, Dad1, Cabin 1, and Rtl1), that is responsible
for its insulator activity, was suggestive of the existence of a
local change in chromatin structure flanking the retrotransposon
(Román et al., 2011b). B1-X35S established a chromatin barrier
upstream and downstream of its gene-specific position that
resulted in an AhR/Slug-dependent enrichment inme3H3K9 and
me3H3K27 repressive marks. We proposed from this study that
AhR-dependent transcription of B1-X35S triggers a repressive
mechanism by acting as an insulator and heterochromatin
barrier. Nevertheless, we could not determine at that time
the precise mechanism through which transposon-derived non-
coding RNA transcripts could repress gene expression.
Experiments performed in human embryonic carcinoma
NTERA-2 cells helped answer such question. Differentiation
of NTERA-2 cells with retinoic acid (RA) produced a marked
increase in AHR protein levels that was followed by its nuclear
translocation and transcriptional activation (Morales-Hernández
et al., 2016). The search for AHR targets led to the identification
of pluripotency inducing genes NANOG and OCT4 as those
having an Alu element in their promoters that contain active
XRE and E-box sites for AHR and Slug/Snai2 binding. Notably,
repression of NANOG and OCT4mRNAs required AHR binding
to the Alu element and its transcription by RNA polymerase
III, thus producing Alu-derived non-coding RNA transcripts
that will have a prominent role in the repressive process. RNA
sequencing (RNAseq) allowed the identification of NANOG-
Alu and OCT4-Alu derived transcripts. The analysis of the
microRNA machinery of NTERA-2 cells using RISC (RNA-
induced silencing complex) inhibitors, dominant-negative forms
of Microprocessor components DROSHA and DGCR8 and
AGO-2 driven RNA immunoprecipitation (RIP), led us to
propose a model in which NANOG-Alu derived transcripts were
processed through the miRNA pathway to generate small non-
coding RNAs complementary to the 3′UTR region (unstranslated
region) of NANOG and OCT4. Such complementarity would
eventually reduce the mRNA levels of both genes in cis and
trans, respectively. Consistently, NTERA-2 cells engineered to
stably express a small-hairpin RNA for AHR (sh-AHR) had a
basal undifferentiated status, did not respond to RA-induced
differentiation and had a marked reduction in non-coding
RNA transcripts from NANOG and OCT4 Alus (Morales-
Hernández et al., 2016). This study also revealed that AHR
induces differentiation in human carcinoma cells and that its
downmodulation promotes undifferentiation. This functional
interaction of AHR with mobile genetic elements in the control
of gene expression represents a novel mechanism that could
contribute to establish gene expression programs required
for cellular reprogramming and for the maintenance of an
undifferentiated status.
Epigenetic Mechanisms
Epigenetic modifications refer to dynamic changes introduced
in genes by specialized enzymes, which do not alter their
DNA nucleotide sequence itself, but instead modify how
they are transcribed. DNA methylation, post-translational
modification of histones and chromatin remodeling are the main
epigenetic modifications so far described, and alteration of these
mechanisms is known to be associated with different human
pathologies. Initial cancer driving events involve genome-wide
epigenetic silencing of transcription factors that disrupt gene
networks, specifically, those targeted by EZH2/polycomb, p53,
c-Myc, and AhR (Locke et al., 2015). For instance, in MCF7
human breast cancer cells, AhR activation was linked to silencing
of BRCA1 by recruitment of DNA methyltransferases to its
promoter region (Papoutsis et al., 2015). In human keratinocytes,
AhR was reported to induce silencing and hypermethylation
of the CDKN2A (p16) tumor suppressor gene and inhibition
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of p53 signaling (Frauenstein et al., 2013). However, within
this epigenetic context, more efforts are necessary to unravel
the precise connection between epigenetic modifications and
transcriptional regulation of AhR, either through the receptor
itself or through its target genes.
Regarding the regulation of AhR expression, we described
for the first time that AhR is an epigenetically regulated gene
(Mulero-Navarro et al., 2006). The human AHR promoter has
CpG islands susceptible to be methylated and that could result
in gene silencing. In particular, acute lymphoblastic leukemia
(ALL) REH and chronic myeloid leukemia K562 cell lines had
high levels of AhR promoter methylation and did not express
detectable levels of receptor under basal conditions (Mulero-
Navarro et al., 2006). Furthermore, AhR was methylated in 33%
of primary human ALL tumors, suggesting that AhR silencing in
this tumor type could hamper the likely tumor suppressor activity
of this receptor. Interestingly, the frequency of AhR methylation
in ALL is similar to that found for other tumor suppressors genes
such as p53, p73, p15, and p16 (Mulero-Navarro et al., 2006). In
diffuse large B-cell lymphoma (DLBCL) cell lines,AhR expression
was restored not only by the DNAmethyl transferase inhibitor 5-
Aza-2′ deoxycytidine (AZA), but also by the histone deacetylase
inhibitor Trichostatin A, indicating that differences in histone
acetylation may also alter AhR expression (Ding et al., 2015).
The latter study confirmed, using knockdown experiments and
those two epigenetic inhibitors, that the AhR/ARNT complex
regulatesMEF2B and BCL6.MEF2B codes for a key transcription
factor that cooperates with co-repressors and histone-modifying
enzymes to regulate gene expression while BCL6 is a proto-
oncogene selectively expressed in germinal center B-cells, in
which it induces the expression of the germinal center markers
LMO2 and MYBL1. Thus, AhR-dependent upregulation of
wild-type MEF2B could add an additional layer of epigenetic
regulation in DLBCL besides canonical BCL6 translocations,
BCL6 hyper-mutation andMEF2Bmutations (Ding et al., 2015).
There are some evidences indicating that AhR and histone
deacetylases become part of a common epigenetic regulatory
machinery. AhR and NAD+-dependent deacetylase Sirtuin 1
(SIRT1) were analyzed in different disorders such as human
vascular senescence and atopic dermatitis. AhR regulates
cellular senescence of human endothelial cells mediated by
oxidative stress. Specifically, AhR activation by indoxyl sulfate
(IS) in human umbilical vein endothelial cells (HUVECs)
accelerates senescence by suppressing the NAD+-dependent
SIRT1 with a concomitant decrease in NAD+ levels and in
intracellular nicotinamide phospho-ribosyl-transferase (iNampt)
activity (Koizumi et al., 2014). These results suggest that the IS-
AhR-SIRT1 pathway plays an important role in the pathogenesis
of vascular senescence. AhR also appears to be a relevant
regulator of the skin barrier, at least in part because of its role
in xenobiotic detoxification. AhR activation by coal tar induces
skin barrier repair with enhanced expression of the structural
skin barrier protein filagrin (FLG) (van den Bogaard et al.,
2015). As one of the available treatments for atopic dermatitis
(AD), coal tar was found to promote epidermal differentiation
by activating AhR. Combined activation of SIRT1 and AhR/AKT
improved skin barrier repair and the therapeutic effects of coal tar
on atopic dermatitis. Mechanistically, SIRT1 positively regulated
AhR activation, which, in turn, enhanced AhR and AhR/AKT-
induced FLG expression. SIRT1 loss in keratinocytes and mouse
skin inhibits basal and ligand-induced AhR activity.
In addition to promoter hypermethylation and histone
modifications, deregulation of micro-RNAs (miRNAs) as
epigenetic and post-transcriptional regulators add another
level of control to AhR functions in normal physiology
and pathogenesis. miRNAs are small, 19-25 nucleotides
long non-protein-coding RNAs that, once matured, bind to
3′-untranslated regions (3′UTR) of target messenger RNA
molecules (mRNAs). miRNA binding to its cognate mRNA
results in posttranscriptional suppression of gene expression
through cleavage of the target mRNA molecule. miRNAs
are involved in normal eukaryotic cellular functions like
proliferation, differentiation, apoptosis and development and,
as a result, their deregulation is associated with various diseases
(e.g., in immunity, autoimmune disease, and cancer) (Lu et al.,
2005). To date, the implication of the miRNAmachinery in AhR-
dependent signaling, and vice versa, is mostly under investigated.
Original findings suggested that AhR is an important regulator
of T cell differentiation (Kimura et al., 2008; Quintana et al.,
2008; Veldhoen et al., 2008; Gandhi et al., 2010). In mouse
models of experimental autoimmune encephalitis and collagen-
induced arthritis, several laboratories have demonstrated the
involvement of miRNA-based mechanisms in AhR-dependent
differentiation of immune cells. In particular, it was shown
that whereas Th17 differentiation via AhR depends on the
miR132/212 cluster, Treg differentiation from naïve T cells by
Transforming growth factor-β (TGF-β), with or without AhR
ligands TCDD or 6-formylindolo[3,2-b]carbazole (FICZ), did
not show significant differences in control and miR-132/212
double knock-out (DKO) mice. These data indicate that the
miR-132/212 cluster participates in AhR-mediated development
of Th17, but not Treg cells (Nakahama et al., 2013). Additional
work has addressed the role of the AhR-inducible miR-132/212
cluster in inflammatory and ulcerative colitis in mice. The results
show that AhR has specific functions in different immune cell
populations: the AhR-inducible miR-132/212 cluster promoted
inflammatory responses by inducing Th17 cells and suppressing
the development of IL-10-producing T cells (Chinen et al.,
2015). In breast cancer, miR-132, but not miR-212, inhibited
cell proliferation and metastasis mediated by the NH1 gene
(Hematological and Neurological expressed gene-1) (Zhang
et al., 2014). In contrast, AhR activation by TCDD and 3.3′-
diindolylmethane (DIM) regulated miR-132/212 expression
in MDA-MB-231 and T47D breast cancer cells. Chromatin
immunoprecipitation (ChIP) assays demonstrated AhR binding
to the two xenobiotic responsive elements (XRE) located within
1 kbp of the upstream promoter of the miR-132/212 genes,
thus supporting a direct transcriptional regulatory mechanism.
Besides, inhibition of miR-212/132 in cells treated with TCDD
and DIM mitigated the anti-invasive effects of these molecules,
suggesting that miR-212/132 mediate, at least partially, the
anti-metastatic effects of prototypical AhR ligands. Although
more research needs to be done, it appears plausible that
other molecules, probably other miRNAs, play a role in the
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anti-invasive effects of AhR. In fact, functional interactions
between AhR and miR-335 have been described in breast cancer.
miR-335 is an anti-metastatic miRNA that can be induced by
TCDD and 6-methyl-1,3,8-trichlorodibenzofuran (MCDF) in
estrogen receptor (ERα)-negative breast cancer cells. miR-335
over-expression inhibited invasion and metastasis of MDA-
MB-231 LM2 cells in vivo (Tavazoie et al., 2008). Both TCDD
and MCDF induced miR-335 and decreased SOX-4 expression,
whereas MCDF also inhibited MDA-MB-231 LM2 metastasis to
the lungs in in vivo tail vein injection assays. The mechanistic
connection between AhR and miR-335 was demonstrated by
the fact that AhR knockdown abolished the effects of TCDD
and MCDF on miR-335 and SOX4 expression as well as the
interaction of miR-335 with the SOX4 3′-UTR region (Tavazoie
et al., 2008).
NEW ROLES OF AHR IN PHYSIOLOGICAL
AND PATHOLOGICAL PROCESSES
The study of the physiological functions of AhR, and
consequently, of the pathologies in which this receptor might
be involved has attracted the interest of many laboratories in
recent years. In addition to its well-known functions related
to cell proliferation, adhesion and migration, there are other
cellular processes where AhR is emerging as a relevant molecular
intermediate. Among them, we will analyze here how AhR
expression influences cell differentiation and pluripotency and
also its probable role in maintaining a stem phenotype.
Cell Differentiation, Pluripotency, and
Stemness
The implication of AhR in cell differentiation was described in
early reports. Studies using phorbol ester as inducer, revealed that
differentiation of promyelocytic HL-60 and erythroblastic HEL
cells to monocytes increased the levels of transcriptionally active
AhR (Hayashi et al., 1995). Moreover, treatment of pregnant mice
with the AhR ligand TCDD demonstrated that this carcinogen
acts directly on the embryo proper at the pre-implantation
stage and that it accelerates the differentiation program
during organogenesis (Blankenship et al., 1993), suggesting that
AhR supports differentiation in vivo. In agreement with that
hypothesis, recent findings have shown that AHR activation
by TCDD during mouse pregnancy blocked the ability of
hematopoietic stem cells (HSC) for long-term self-renewal
(Laiosa et al., 2015) and that sustained AhR activation during
early differentiation of mouse embryonic stem cells impairs
signaling critical for the ontogeny of cardiac mesoderm and
cardiomyocyte functions (Wang et al., 2016).
Genome-wide ChIP/chip analysis using wild type Hepa-1c1c7
mouse hepatocellular carcinoma cells and its AhR-deficient c37
derivative, have identified gene clusters regulated by AhR with
a suspected implication in cell differentiation, patterning and
development under basal cell conditions (Sartor et al., 2009).
The effects of AhR on differentiation in absence of xenobiotics
were also described in former reports. Experiments aiming to
differentiate embryonic fibroblasts from wild type and AhR-
null mice into adipocytes revealed that lack of AhR altered
spontaneous differentiation and cell senescence, suggesting that
AhR is an early regulator of adipocyte differentiation (Alexander
et al., 1998). Accordingly, modulating AhR levels in 3T3-
L1 murine fibroblasts by either receptor over-expression or
knockdown showed that high receptor levels could suppress
morphological adipocyte differentiation and the induction of
adipogenesis-related genes, then confirming that AhR is a
negative regulator of adipose differentiation of fibroblast cells
(Shimba et al., 2001). But perhaps one of the fields where AhR
has been more intensively scrutinized regarding differentiation is
the immune system. A previous excellent review is recommended
for a detail analysis of the role of AhR in immune differentiation
of barrier organs such as skin, gut, and lung epithelia (Esser
and Rannug, 2015). The reciprocal correlation between the
generation of Treg cells expressing the transcription factor Foxp3
and pro-inflammatory T cells producing interleukin-17 (Th17)
has been intensely investigated in the context of the immune
system differentiation (Esser et al., 2009). Parallel reports revealed
that AhR was required and regulated the differentiation of both
Treg and Th17 lymphocytes in vitro and that such process
required the presence of an externally added ligand such as
FICZ or a molecule generated in the culture medium not yet
identified (Quintana et al., 2008; Veldhoen et al., 2009). Latter
efforts trying to identify ligands that modulate Treg and Th17
differentiation have concluded that whereas Th17 differentiation
involves a XRE-mediated mechanism, Treg differentiation could
take place by a non-XRE-mediated process and, therefore, that
selective AhR modulators (SAhRM) could be used to modulate
the Th17/Treg balance (Mohinta et al., 2015). There are evidences
that kynurenine (L-Kyn), the first tryptophan metabolite of
the indoleamine 2,3 dioxygenase (IDO) pathway, activates the
AHR at a dose clinically relevant in humans and leads to the
generation of Treg cells in vitro. The role for AHR in this
process is supported by the fact that L-Kyn does not influence
Treg generation in AHR-null T cells and it can activate the
AHR-dependent transcription of classical target genes such as
Cyp1a1 and Cyp1b1 (Mezrich et al., 2010). Moreover, AHR
activation by L-Kyn regulates the expression of alternative target
genes in dentritic cells including Tgfβ1 and Ido1, which, in
turn, will promote the expression of anti-inflammatory genes
(Nuti et al., 2014). Other potential AHR ligand is 2-(1′H-indole-
3′-carbonyl)-thiazole-4-carboxylic acid methyl ester (ITE). It
promotes the induction of active immunologic tolerance by
exerting direct effects on dendritic cells and T lymphocytes, being
considered as a nontoxic endogenous AHR ligand potentially
useful for the treatment of autoimmune disorders (Quintana
et al., 2010). Interestingly, AhR can cooperate with the hypoxia-
inducible factor-α (HIF-1α in the differentiation of type 1
regulatory T cell (Tr1) through metabolic reprogramming. At
early stages of differentiation, HIF-1α drives Tr1 metabolic
reprogramming whereas, at later times, AhR would induce HIF-
1α degradation to take control of Tr1 metabolism (Mascanfroni
et al., 2015). The differentiation promoting activity of AhR
has been observed in additional cell types. Treatment of
primary mouse keratinocytes with AhR antagonists CH223191
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and GNF351 impaired their terminal differentiation while
transcriptomic analysis of keratinocytes isolated from AhR+/+
and AhR-/- mice has generated a differential gene expression
pattern in which terminal differentiation genes were significantly
inhibited in AhR-/- keratinocytes (van den Bogaard et al., 2015).
However, AhR does not seem to have a general contribution
to immune and T cell differentiation since it is not seem to be
required for the differentiation of T cytotoxic 17 (Tc17) cells
(Hayes et al., 2014). Although AhR has a pro-differentiation role
in the majority of cell types investigated, a recent study indicated
that receptor activation by TCDD inhibited proliferation and
differentiation of pre-osteoblasts MC3T3-E1 cells in a dose-
dependent manner, and that pretreatment with the AhR
antagonist CH-223191 restored the differentiation potential of
MC3T3-E1 cells (Yu et al., 2014). Thus, it appears that AhR
has cell-type specific effects on cell differentiation, as it is
already known with respect to cell proliferation and migration
(Pohjanvirta, 2012).
It appears evident that AhR is relevant for cell differentiation.
Recent reports are also showing that transposable elements
can regulate embryonic cell differentiation. Since AhR controls
the expression of murine and human retrotranspons, the link
between AhR, retrotransposons and cell differentiation seems
likely. In addition to our previous work demonstrating that
differentiation of human carcinoma NTERA-2 cells can be
induced by an AHR-regulated Alu retrotransposon (Morales-
Hernández et al., 2016), additional studies (see Section AhR
in the Control of Gene Expression through Mobile Genetic
Elements above) have identified a LINE-1 element that responds
to AhR ligands during the differentiation of renal carcinoma
cells (Ramos et al., 2011) and a LINE-1 that can retrotranspose
upon AhR activation by food-borne mutagens (Okudaira et al.,
2013). It will be important to establish whether AhR has a more
general role in the control of transposable elements known to
contribute to cell differentiation. A complementary view to this
question is to search for transposable elements that may regulate
pluripotency and stemness through the AhR. Although this issue
remains to be addressed in detail, AhR is connected to cell
stemness since its expression is transcriptionally repressed in
mouse embryonic stem cells by a signaling pathway involving
pluripotency factors OCT3/4, NANOG, SOX2 and polycomb
proteins. Such repression is reversible so that rapid AhR
upregulation may trigger embryonic stem cell differentiation (Ko
et al., 2013). In addition, the anti-allergy drug tranilast can revert
differentiation during the reprogramming of mouse embryonic
fibroblasts to induced-pluripotent stem (iPS) cells by the AhR-
dependent control of miR-302 (Hu et al., 2013). Transposons
are also coupled with pluripotency and stemness. Upregulation
of Alu retrotransposons in human adult stem cells results in
nuclear cytotoxicity associated to permanent DNA damage, loss
of efficient DNA repair and senescence; Alu elements may
have a causal role in the process because its downmodulation
reverses the senescent phenotype and rescues self-renewal and
the expression of pluripotency regulators (Wang et al., 2011).
Retrotransposon-derived transcripts are also relevant in the
maturation of germinal cells, in particular of spermatocytes.
Piwi-interacting RNAs (piRNAs) produced from transposons
are responsible for the degradation of mRNAs and long non-
coding RNAs (lncRNAs) in late spermatocyte differentiation,
supporting that retrotransposons influence pluripotency and
maturation of the male germline (Watanabe et al., 2015). High
throughout analysis of the nuclear and cytosolic transcriptome
of human and mouse stem cells identified a novel class of stem
cell-specific transcripts, including long terminal repeat (LTR)-
derived transcripts, presumably associated to gene enhancer
regions relevant for pluripotency (Fort et al., 2014). In
agreement with that possibility, it has been observed that certain
endogenous retroelements weremarkedly overexpressed whereas
others were repressed during the reprogramming of mouse
embryonic fibroblasts, human CD34+ cells and human primary
hepatocytes to iPS cells. To some extent, that expression pattern
of retrotransposon expression found in iPS cells resembles
that found in embryonic stem cells. Importantly, during
reprogramming and in established iPS cells, the upregulation of
specific retrotransposons significantly influenced the expression
of nearby genes, thus supporting a gene regulatory function for
those repetitive elements in pluripotency and stemness (Friedli
et al., 2014). Altogether, we propose the existence of a functional
link between AhR and differentiation and between differentiation
and pluripotency with transposable elements. Notably, studies
are starting to emerge establishing a signaling pathway that
connects AhR with differentiation/pluripotency and both with
retrotransposon expression. This is not surprising considering
the very probable relevance of mobile genetic elements in the
control of cell function.
Deregulation of AhR-Related Cellular and
Tissue Differentiation
AhR has a ubiquitous cell and tissue distribution and it is
highly conserved in evolution, which supported its implication
in different physiological processes (Section Cell Differentiation,
Pluripotency, and Stemness). Consequently, alterations in AhR-
dependent signaling may cause different developmental and
homeostatic disorders in the organism. In this review, we will
focus in alterations affecting the cardiac, hematopoietic, epithelial
and hepatic systems.
The fact that AhR has a relevant contribution to the control of
cell differentiation under physiological conditions suggests that it
may also be important for differentiation-related pathologies. In
a panel of metastatic and invasive human breast cancer cell lines,
AhR activation by exogenous ligand blocked their anchorage-
independent growth and metastatic potential while promoting
their differentiation to a less invasive phenotype. Consistently,
AhR knockdown impaired the protective effects of receptor
expression and rescued cell motility and invasion, suggesting
that AhR-induced differentiation could be a valuable tool in
breast cancer treatment (Hall et al., 2010). Neuroblastoma is
among the most common malignant diseases of the infancy.
The comparative analysis of neuroblastoma tumors having or
lacking amplification of the prognostic MYCN marker revealed
that AhR expression was inversely correlated with MYCN
amplification and, importantly, with an increased grade of tumor
differentiation. Gene expression analysis identified MYCN as a
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novel AhR target gene repressed in neuroblastoma cells by a
mechanism involving the transcription factor E2F1 (Wu et al.,
2014). AhR is also involved in leukemia cell differentiation.
HL-60 human myeloblastic leukemia cells have been used as
a model because they can be readily differentiated by retinoic
acid (RA) treatment. RA increased AHR levels during HL-
60 differentiation, in parallel with a reduction in the levels of
the pluripotency and stem cell marker OCT4. The implication
of AHR in the mechanism was confirmed by the fact that
receptor overexpression inhibited OCT4 and ALDH1 levels
and exacerbated RA-induced granulocytic differentiation of
HL-60 cells as determined by the upregulation of CD38 and
Cd11b markers (Bunaciu and Yen, 2011). Furthermore, the
same laboratory also demonstrated that AHR activation by
the non-toxic FICZ ligand enhanced RA-induced granulocytic
differentiation of HL-60 cells likely through the RAF-MEK-
ERK signaling pathway and downstream targets. In agreement,
RA and FICZ co-treatment increased AHR levels and its
transcriptional activity for typical target genes such as CYP1A2
and p47phox (Bunaciu and Yen, 2013). The AHR agonist
VAF347 also increased receptor levels in RA-treated HL-60
cells concomitantly with their differentiation to a granulocytic
lineage; further supporting that AHR upregulation in leukemia
cells favors a differentiated phenotype (Ibabao et al., 2015).
VAF347 was also able to promote the differentiation of IL-22-
producing Th cells from naïve CD4+ Th cells, suggesting that
AhR activation could increase the beneficial effects of IL-22 while
preventing the secretion of pro-inflammatory cytokines (Baba
et al., 2012).
We have recently described that the guanine nucleotide
exchange factor Vav3, a protooncogene that regulates the
activation of Rho and Rac GTPases, is an AhR transcriptional
target in murine embryonic fibroblasts. Notably, AhR-deficient
mice develop respiratory and cardiovascular phenotypes
that resemble those of Vav3-/- mice including hypertension,
tachypnea, and sympathetic excitation. Similarly to Vav3-
deficient mice, AhR-/- animals develop cardiovascular
remodeling characterized by concentric left ventricular
hypertrophy, thickening of the arterial wall, increased numbers
of vascular smooth muscle cells in arterial walls and extensive
fibrosis in the heart and kidneys (Sauzeau et al., 2011). Earlier
studies did also show that AhR-/- mice had cardiac hypertrophy,
blood pressure overload and elevated levels of the proteins
endothelin 1 (ET-1), angiotensin-2, β-myosin heavy chain
and atrial natriuretic factor (Lund et al., 2003). Interestingly,
the higher risk for developing cardiovascular pathologies in
chronic kidney disease patients could be due to exposure to
uremic toxins derived from tryptophan metabolism. Tryptophan
metabolites could in turn activate AhR and induce the generation
of reactive oxygen species contributing to leukocyte activation
and inflammation (Sallée et al., 2014).
The ability to self-renew, and the balance between the pool
of HSCs and the different subsets of differentiated hematopoietic
progenitors are controlled by a tightly regulated mechanism.
AhR is acquiring an emerging role in the deregulation of
these processes. Prolonged loss of AhR results in sensitivity to
stress and in premature exhaustion and aberrant changes in
HSCs that develop into a myeloproliferative disorder in aged
mice (Singh et al., 2014). Altered AHR expression and activity
have also been described in human leukemia and lymphoma
cells (Hayashibara et al., 2003; Mulero-Navarro et al., 2006).
Additional work has identified intermediate proteins of the AhR
signaling pathway that are rapidly and robustly activated by
small molecules (SR1, LGC006, UM729) in normal and leukemic
stem cells in culture (Boitano et al., 2010; Pabst et al., 2014).
In acute myeloid leukemia (AML) cells, the CD34+CD15−
population increases following AhR suppression by a block
in differentiation rather than by an increase in proliferation.
Moreover, the levels of CD34+CD38− and CD34+CD38+
compartments benefitted from the presence of the SR1 and
UM729 molecules with respect to untreated cultures (Pabst et al.,
2014). Dendritic cells (DC)-based immunotherapy is actually
considered an important tool in the treatment of patients. Tumor
cells, myeloid-derived suppressor cells and tumor-associated
macrophages keep a potent immunosuppressive environment
to avoid DC maturation. The acquisition of maturation-
associated genes, and their contribution to the maintenance of
an immature state of monocyte-derived dendritic cells (MDDCs)
and myeloid DCs are partly dependent on AhR activity. In fact,
the transcriptional activity of AhR appears to be involved in
the ERK-dependent profile of gene expression in MDDC cells.
ERK up-regulates CCL2 expression, a chemokine constitutively
produced by immature MDDCs, while impairing the expression
of maturation markers of dendritic cells such as RUNX3, ITGB7
and IDO1 (Aguilera-Montilla et al., 2013). Furthermore, the
MEK-ERK signaling pathway also regulates antigen capture
and lymph node homing. MEK inhibition likely increases AhR
transcriptional activity in MDDC cells because the AhR partial
antagonist α-naphtoflavone (α-NF) impaired U0126-induced
gene up-regulation. Moreover, U0126 treatment led to in vivo
occupancy of AhR-binding sites followed by a reduction in
total AhR protein levels, suggesting the generation of a pool of
transcriptionally active receptor byMEK inhibition. The immune
system is very sensitive to AhR-mediated toxicity and responds
to particularly low concentrations of chemicals (Kerkvliet et al.,
2002), thus protecting the organism against different insults
including toxins. AhR participates in Th17 cell differentiation
through the regulation of Stat1, with whom it forms a complex
in macrophages to negatively regulate NF-κB-mediated pro-
inflammatory responses. Besides, AhR interacts with c-Maf to
promote the differentiation of type 1 regulatory T cells induced
by IL-27. The compiled data suggest that AhR playsmultiple roles
in distinct immune cell populations (Apetoh et al., 2010).
Chloracne is a skin disease that can be induced by
TCDD in humans. The molecular mechanism driving chloracne
is AhR-related and it seemingly involves both stem cells
and keratinocytes through a terminal differentiation process
activated by filaggrin (Sutter et al., 2011). Moreover, the skin
inflammatory response known as contact dermatitis is triggered
by keratinocytes in which AhR is constitutively active. In this
regard, the major role of AhR in skin pathologies could be to
modulate the expansion of initiated stem cells and keratinocytes
that generate anti-apoptotic signals (Ikuta et al., 2009). In human
melanoma, AhR regulates aldehyde dehydrogenase to block
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melanoma tumorigenesis and metastasis (Contador-Troca et al.,
2015). We have recently reported that stable AhR knockdown
in B16F10 mouse melanoma cells enhanced their primary
tumorigenicity and their metastatic potential to the lungs,
whereas constitutive AhR activation strongly blocked melanoma
progression. Interestingly, AhR knockdown increased melanoma
cell migration and invasion and the expression of mesenchymal
markers α-smooth muscle actin (α-SMA) and Snail. Moreover,
the pro-tumoral phenotype caused by AhR depletion in the
tumor cell (cell autonomous) required AhR expression in the
microenvironment as AhR-/- mice could not support tumor
growth and metastatization of AhR-depleted cells (Contador-
Troca et al., 2013).
There is considerable evidence to support the critical role
played by AhR and AhR-regulated genes in human and murine
hepatocarcinogenesis. For instance, it has been shown that
hexachlorobenzene (HCB) induces the expression of AhR in
rat liver pre-neoplastic foci and in human hepatocarcinoma
HepG2 cells (de Tomaso Portaz et al., 2015). AhR activation is
associated with the disruption of cell-cell contacts in liver stem-
like WB F344 cells, suggesting that it could contribute to the
release of liver metastasis (Köhle et al., 1999; Weiss et al., 2008).
Accordingly, TCDD releases confluent WB-F344 cells from
contact inhibition and stimulates cell growth via activation of Jun
D and Cyclin A (Weiss et al., 2008). In agreement with a positive
effect of AhR in liver growth,AhR-/-mice show reduced liver size,
portal fibrosis and impaired induction of detoxifying enzymes
that could compromise its function (Fernandez-Salguero et al.,
1995; Peterson et al., 2000; Corchero and Fernández-Salguero,
2005). Some of these phenotypes in AhR-null livers appear to be
related to the over-activation of TGFβ due to the up-regulation
in the extracellular matrix of its latency protein LTBP-1, which
was in fact identified as a novel AhR target gene (Santiago-Josefat
et al., 2004; Corchero and Fernández-Salguero, 2005; Gomez-
Duran et al., 2006, 2008). The scenario in the liver appears
more complex since AhR also regulates RA levels and retinoid
homeostasis (Andreola et al., 1997, 2004), which are functionally
related to TGFβ and to cell growth and differentiation. Further
work is needed to clearly define the pathological consequences
of altered AhR expression in the liver. Recently, the role of AhR
in the differentiation process of hepatic stem/progenitor cells
(HpSC) has been regarded as a new important aspect in receptor
biology. The effects of AhR on hepatic stem cells has been
studied by Harril and coworkers after defining successful culture
conditions for rat hepatic stem cells treated with hyaluronans,
TCDD, FICZ andDIM. They showed that chronic administration
of TCDD to female rats produced pathological changes that
included hepatocellular hypertrophy and proliferation of HpSC
(Harrill et al., 2015).
MEDICAL APPROACH OF AHR
In this section, we will discuss possible AhR ligand candidates
and AhR itself both as a potential therapeutic target and as
a beneficial molecule whose regulation could improve human
health status.
AhR as a Therapeutic Target in Human
Disease
The identification of AhR ligands with well-described health-
promoting effects and/or beneficial pharmaceutical properties
has prompted research on the development of drugs to target
AhR for the treatment of diseases including specific tumors,
immune disorders, inflammatory disease and to enhance the
production of hematopoietic stem cells. The development of
drugs that target AhR is based on selective AhR modulators
(SAhRMs), in which a ligand exhibits tissue-specific AhR
agonistic or antagonistic activity (Jin et al., 2012). Tissue-specific
differences in agonistic or antagonistic activity of a ligand are
due to multiple factors including ligand-induced conformational
changes in the receptor and in subsequent interactions with
critical co-activators and co-repressors. Various classes of AhR
ligands, and different molecular species within the same class,
can differentially modulate AhR activity causing different gene
expression outcomes. For this reason, AhR may become a
potentially important drug target that can be efficiently regulated
in a cell type-specific manner.
As AhR is highly expressed in a wide panel of tumors,
molecules with antagonistic AhR activity could be considered
potential candidates for the treatment of such diseases. The best
known antagonist of AhR is alpha-naphthoflavone, although it
also has weak agonist activity at relatively high concentrations
(Gasiewicz and Rucci, 1991). A high-affinity AhR antagonist,
StemRegenin 1 (SR1), has been recently developed that increases
the proliferation of human hematopoietic stem cells in vitro
(Boitano et al., 2010). Interestingly, culture with SR1 had no
effect on murine HSCs but expanded the pool of CD34+ cells
from the bone marrow of humans, monkeys (cynomologous
and rhesus), and dogs. Potent effects of the candidate AhR
ligand bilirubin (Kerkvliet, 2009) and ITE (Nuti et al., 2014)
on the immune system have also been reported. In particular,
treatment of mice with bilirubin suppressed the development of
autoimmune disease whereas depletion of endogenous bilirubin
significantly exacerbated the disease (Kerkvliet, 2009). The
administration of synthetic ITE reduces OCT4 levels and induces
the differentiation of stem-like cancer cells, a process that impairs
their tumorigenic potential in both subcutaneous and orthotopic
xenograft tumor models (Cheng et al., 2015). The novel roles
of tryptophan derivatives (e.g., ITE), together with the likely
implication of the AhR pathway in regulating cell stemness, open
interesting new therapeutic avenues to target stem-like cancer
cells. Moreover, in ovarian cancer, it has been demonstrated that
ITE regulates cancer cell proliferation and migration via AhR
using in vitro and/or in vivo models. This potential anti-ovarian
cancer activity of AhR could help optimize strategies for ovarian
cancer therapy (Wang et al., 2013).
Benefits from the Use of AhR Ligands in a
Balanced Diet
Among the numerous plant-derived nutrients and phyto-
chemicals present in the human diet, flavonoids are the most
abundant and are ubiquitous in fruits, vegetables, tea and
wine. Interestingly, the quercetin, apigenin and kaempferol
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present in certain foods (e.g., rosehip, linden flower, honey,
grapes, and tarhana) mediate an agonist/antagonist synergistic
effect of AhR activity in different cell types (Van der Heiden
et al., 2009). Furthermore, many flavonoids have diverse health
promoting effects, including anti-allergic and anti-inflammatory
activities (Kawai et al., 2007; Benavente-García and Castillo,
2008). In addition, the dietary flavonoid naringenin induces
the generation of regulatory Treg cells by an AhR-mediated
pathway (Wang et al., 2012). Recent studies have also shown that
dietary indoles suppressed hypersensitivity by inducing a switch
from pro-inflammatory Th17 to anti-inflammatory Treg cells
through the generation of a specific miRNA profile (Singh et al.,
2016). Interestingly, the flavone-based antagonist resveratrol
has gained considerable interest due to its apparent beneficial
effects on human health. Resveratrol inhibited transcription of
the target gene CYP1A1 in vitro by preventing AhR activation
(Ciolino et al., 1998). Importantly, indole glucosinolates present
in cruciferous vegetables are degraded to indole-3-carbinol (I3C)
and indolo[3,2b]carbazole, the latter having high AhR affinity
(Bjeldanes et al., 1991). As a nutritional supplement, daily
administration of I3C, at doses of 400mg and 800 mg, was well
tolerated in a phase I clinical trial in 17 premenopausal women
(Reed et al., 2005). Probiotic bacteria and yeast belonging to the
microflora of the human intestine and skin are able to produce
AhR ligands (e.g., indole-3-aldehyde, indirubin) intended to
enhance the AhR-mediated barrier function (Magiatis et al., 2013;
Fukumoto et al., 2014). Bilirubin is an antioxidant AhR ligand
that can activate UDP glucuronosyltransferase 1A1 (UGT1A1) in
a negative auto-regulatory feedback loop (Togawa et al., 2008).
Maternal exposure to AhR agonists has been proposed as a
risk factor for breast cancer in the offspring through epigenetic
inhibition of the tumor suppressor BRCA-1 (Breast cancer 1),
whereas dietary AhR antagonists may exert protective effects
against such disease (Papoutsis et al., 2015).
CONCLUSIONS AND FUTURE
PERSPECTIVES
A main conclusion that can be obtained from recent studies
dealing with the implication of the dioxin receptor in physiology
is that this receptor is involved in significantly more cellular
processes that initially anticipated. It is clearly established
that AhR is required for an ample set of toxicological and
carcinogenic responses against environmental compounds. Its
relevant contribution to the regulation of signaling pathways that
control cellular functions such as proliferation, adhesion and
migration is also generally accepted. AhR is known to participate
in the homeostasis of different tissues and organs and in the
pathological processes that result from their dysfunction. The
critical importance of the balance between cell differentiation
and pluripotency has attracted a great deal of attention toward
AhR. The immune system, epithelia from different embryonic
origins, the germline, adipose tissue and bone cells have been
used to conclude that, with some exceptions, the AhR promotes
differentiation. The use of murine and human experimental
models in which AhR expression has been depleted confirms
the induction of an undifferentiated and more pluripotent
phenotype. AhR may modulate cell differentiation by acting
as a direct transcription factor, but also by regulating the
expression of retrotransposons whose transcripts would finally
repress stemness genes. This represents a novel and more
complex mechanism of gene regulation that transformed cells
could use to scape differentiation through AhR inhibition. Since
altered AhR expression can be associated to human disease,
it is reasonable to propose that the design of specific and
selective AhR modulators may have therapeutic value in the
treatment of pathologies such as undifferentiated and highly
malignant tumors. Another point of interest relates to the
inclusion in the diet of molecules acting through AhR that could
contribute to a better health status by preventing undesired
events of dedifferentiation and the acquisition of a stem-like
phenotype leading to cell transformation. Future work will
probably pursue the identification of molecular intermediates
and of yet undetermined signaling pathways in which AhR could
have a central role in the equilibrium between differentiation and
pluripotency. Presumably, the investigation of mobile repetitive
elements will play a significant part in this field.
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